TOMDF (Todos Medical) Short-Term Debt: $5.86 Mil (As of Sep. 2022)


What is Todos Medical Short-Term Debt?

Todos Medical TOMDF -90.00% Short-Term Debt is $5.86 Mil as of Sep. 2022.

Todos Medical's Short-Term Debt for the quarter that ended in Sep. 2022 was $5.86 Mil.

Todos Medical's quarterly Short-Term Debt increased from Mar. 2022 ($0.00 Mil) to Jun. 2022 ($4.85 Mil) and increased from Jun. 2022 ($4.85 Mil) to Sep. 2022 ($5.86 Mil).

Todos Medical's annual Short-Term Debt increased from Dec. 2019 ($0.11 Mil) to Dec. 2020 ($2.98 Mil) but then declined from Dec. 2020 ($2.98 Mil) to Dec. 2021 ($2.02 Mil).

Todos Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Todos Medical Short-Term Debt Related Terms

Todos Medical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Todos Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Todos Medical Short-Term Debt Chart

Todos Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.64 0.11 2.98 2.02

Todos Medical Quarterly Data
Dec15 Dec16 Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.21 2.02 0.00 4.85 5.86
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $5.86 Mil mean?
Todos Medical (TOMDF) has a Short-Term Debt of $5.86 Mil as of Sep. 2022.
Is Todos Medical's Short-Term Debt too high?
Todos Medical's current Short-Term Debt is $5.86 Mil.
How does Todos Medical's Short-Term Debt compare to NDRA and IDXG?
Todos Medical's Short-Term Debt of $5.86 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Todos Medical's current Short-Term Debt is $5.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Todos Medical stock overvalued right now?
Todos Medical (TOMDF) has a current Short-Term Debt of $5.86 Mil. The current Short-Term Debt is $5.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Todos Medical (TOMDF), the current Short-Term Debt is $5.86 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Todos Medical Business Description

Address 121 Derech Menachem Begin, 30th Floor, Tel Aviv, ISR, 6701203
Todos Medical Ltd is an in vitro diagnostics company. Its operating segments are Breast Cancer Test, Alzheimer's, and COVID-19 testing. The company generates all of its revenue from the United States.